Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

NS-018 preferentially targets V617F-mutant JAK2

Dec. 21, 2010

Clinical and preclinical data presented on GDC-0941/T-DM1 in HER2+ breast cancer

Dec. 21, 2010

Panobinostat/capecitabine/lapatinib combination is safe in HER2+ breast cancer

Dec. 21, 2010

ClanoTech divulges new inhibitors of VEGFR-2 and VEGFR-3

Dec. 21, 2010

UCB claims new PI3K inhibitors

Dec. 21, 2010

Enzon and NCI begin phase I trials of EZN-2968 and EZN-2208

Dec. 20, 2010

Amira Pharma nominates preclinical candidate in LPA-related program

Dec. 20, 2010

Novel Toll-like receptor 7 agonists discovered

Dec. 20, 2010

MM-302 shows promise to treat HER2-overexpressing tumors

Dec. 20, 2010

Merck KGaA and sanofi-aventis to jointly investigate new anticancer agents

Dec. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...